financetom
Business
financetom
/
Business
/
Wyndham Hotels' Q3 profit beats as ancillary revenue rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wyndham Hotels' Q3 profit beats as ancillary revenue rises
Oct 22, 2025 2:01 PM

Overview

* Wyndham Q3 adjusted EPS beats analyst expectations, adjusted net income also exceeds estimates

* Company system-wide rooms and development pipeline grew 4% year-over-year

* Returned $101 mln to shareholders via share repurchases and dividends

Outlook

* Wyndham revises full-year RevPAR growth to (3%) to (2%)

* Company lowers full-year adjusted EBITDA to $715-$725 mln

* Wyndham expects marketing fund expenses to exceed revenues by $5 mln in 2025

Result Drivers

* SYSTEM GROWTH - Co's system size and development pipeline grew 4% year-over-year, driven by increased development contracts and focus on high-quality expansions

* ANCILLARY REVENUE INCREASE - Ancillary revenues increased 18% compared to Q3 2024, contributing positively to financial results

* ORGANIC ROOM OPENINGS - Record year-to-date organic room openings achieved amid challenging macroeconomic conditions, per CEO Geoff Ballotti

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.46 $1.44

Adjusted (11

EPS Analysts

)

Q3 EPS $1.36

Q3 Beat $112 mln $111.70

Adjusted mln (10

Net Analysts

Income )

Q3 Net $105 mln

Income

Q3 Miss $213 mln $213.50

Adjusted mln (10

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the hotels, motels & cruise lines peer group is "buy"

* Wall Street's median 12-month price target for Wyndham Hotels & Resorts Inc ( WH ) is $99.00, about 18.1% above its October 21 closing price of $81.13

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues
Jun 16, 2025
07:12 AM EDT, 06/16/2025 (MT Newswires) -- DRI Healthcare Trust (DHT-UN.TO, DHT-U.TO) over the weekend said it has been notified by KalVista Pharmaceuticals that the U.S. Food and Drug Administration will miss the June 17 goal date to decide on the new drug application for sebetralstat, due to a heavy workload and resourcing issues. The FDA has not requested additional...
Amazon Web Services to Invest $13.04 Billion in Australia Data Centers
Amazon Web Services to Invest $13.04 Billion in Australia Data Centers
Jun 16, 2025
07:12 AM EDT, 06/16/2025 (MT Newswires) -- Amazon.com ( AMZN ) Web Services plans to invest 20 billion Australian dollars ($13.04 billion) in Australia's data center infrastructure, Prime Minister Anthony Albanese said Saturday. The investment will be made over the next five years and provide technology to support artificial intelligence and other applications at data centers in Melbourne and Sydney....
Lilly to offer higher-dose versions of weight-loss drug on website
Lilly to offer higher-dose versions of weight-loss drug on website
Jun 16, 2025
June 16 (Reuters) - U.S. drugmaker Eli Lilly ( LLY ) said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on its website LillyDirect, with shipments starting in early August. The company said the 12.5 milligrams and 15 mg doses of the drug will be available for $499 per month on the website with...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved